The use of interferon alpha-2b for prevention of novel coronavirus infection in healthcare workers

Khlynina, Yu.O.; Арова, А А; Nevinsky, A.B.

doi:10.20953/1729-9225-2021-2-65-69

Infekc. bolezni

2021

DOI: 10.20953/1729-9225-2021-2-65-69

|View full text |Cite

The use of interferon alpha-2b for prevention of novel coronavirus infection in healthcare workers

Yu.O. Khlynina¹,

А А Арова²,

A.B. Nevinsky³

Abstract: Novel coronavirus infection (COVID-19) caused by SARS-CoV-2 has some specific clinical and immunopathogenic properties. SARS-CoV-2 is a single-stranded RNA virus that belongs to the Coronaviridae family, the Betacoronavirus genus. COVID-19 can be asymptomatic, the most common clinical manifestation of this disease is viral pneumonia. The development of acute respiratory distress syndrome is noted in less than 5% of cases. The entry gates of this virus are the epithelium of the upper respiratory tract and epith… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

2024

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Non-specific prevention of respiratory infections during vaccination against COVID-19

Khasanova,

Soloveva,

Kostinov

et al. 2023

Cytokines and inflammation

View full text Add to dashboard Cite

The novel coronavirus infection (COVID-19) has a suppressive effect on innate immunity, which is a prerequisite for developing strategies to enhance this non-specific link as a preventive measure to protect against other respiratory infections during the ongoing circulation of mutating strains of the SARS-CoV-2 virus. Despite the currently developed and available preventive measures, it has been noted that in persons who have undergone COVID-19, repeated episodes of both coronavirus infection and diseases caused by other pathogens have been recorded. This review analyzes data from the biomedical literature and considers examples of health risks associated with continued infection with pathogens that cause respiratory tract pathologies. It also reflects the ways and approaches of possible preventive measures, the purpose of which is to prevent the development of pathologies of both the respiratory organs and other systems.

show abstract

Non-specific prevention of respiratory infections during vaccination against COVID-19

Khasanova,

Soloveva,

Kostinov

et al. 2023

Cytokines and inflammation

View full text Add to dashboard Cite

show abstract

Prospects for cytokine therapy in acute respiratory viral infections, including COVID-19

Simbirtsev

2024

Cytokines and inflammation

View full text Add to dashboard Cite

Dysregulated cytokine response is the key point for severe acute respiratory infections immunopathogenesis, including COVID-19. That is why two main approaches for cytokine therapy are possible in these cases that depend on the infectious process stage and clinical manifestations severity. Perspective immunotherapy directions for acute respiratory infections could be: intranasal recombinant type I or type III interferon application in the early stage of disease, and anticytokine therapy in order to decrease endogenous proinflammatory cytokine synthesis at the stage of severe pneumonia and cytokine storm development, especially in COVID-19. Recombinant interferon therapy is directed for recovery of endogenous IFN levels decreased due to respiratory viruses pathogenic activity. Both therapeutic approaches could be considered as immunotherapy variants, especially cytokine therapy using recombinant analogs or anticytokine therapy mainly with monoclonal antibodies.

show abstract

Influence of a combined interferon-alpha-containing drug on the course of respiratory diseases in frequently ill children

Zakirova,

Moroz,

Shayapova

et al. 2023

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. Acute respiratory viral infections hold a dominant place in the infectious diseases pattern. There are many drugs that can affect separate arms of the immune response.Aim. To analyze the effectiveness of the systemic use of a combined drug containing interferon-α-2b and a complex immunoglobulin preparation in the treatment of respiratory diseases in frequently ill children.Material and methods. We examined 103 children aged 2-12 years. Upon admission, the children were treated with a combined drug containing interferon a-2b and a complex immunoglobulin preparation (CIP) (Kipferon®) rectally. Children in the control group received standard therapy.Results. Children were admitted to the hospital in the first days of the disease (66.02%), mainly in the moderate form of the disease (96.12%). 81.55% had symptoms of intoxication, catarrhal phenomena and respiratory syndrome. Comparing the time from the onset of the disease when prescribing IFN-α-2b to children, their significantly significant differences were established. Introduction in the early stages of the disease contributes to a faster elimination of all symptoms: fever stopped on average (M ± SD) after 1.76 ± 0.33 and 2.05 ± 0.29 days, respectively, from the moment of admission to the hospital, which was on average 2 days less than in the control group. The transition to a productive cough in the main group occurred on average (M ± SD) after 3.25 ± 0.27 days, in the comparative group - after 5.23 ± 0.31, in the control group - after 8.19 ± 0.42 days. In patients of the main and comparative groups, the length of stay in the hospital was significantly shorter - on average (M ± SD) 8.04 ± 0.81 days than in the control group - 10.56 ± 1.42 days. Hematological parameters returned to normal at an earlier time.Discussion. Rectal route of recombinant IFNi-a2b delivery as suppositories is substantiated with regard to etiopathogenesis and immunology.Conclusion. The article presents the outcomes of the clinical use of Kipferon® as part of the combination therapy and prevention of complications of acute respiratory viral infections in children: reduced duration of intoxication, fever, faster improvement of the auscultatory status of the lungs, improvement of immune status indicators.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The use of interferon alpha-2b for prevention of novel coronavirus infection in healthcare workers

Cited by 4 publications

References 0 publications

Non-specific prevention of respiratory infections during vaccination against COVID-19

Non-specific prevention of respiratory infections during vaccination against COVID-19

Prospects for cytokine therapy in acute respiratory viral infections, including COVID-19

Influence of a combined interferon-alpha-containing drug on the course of respiratory diseases in frequently ill children

Contact Info

Product

Resources

About